Antares nets $47m from first offering since move to Nasdaq
This article was originally published in Scrip
Antares Pharma will earn $47 million in net proceeds to fund development of its Vibex disposable pressure-assisted auto injectors for rheumatoid arthritis and male testosterone deficiency drugs through an underwritten offering of 12.5 million shares of common stock closing on 9 October at $4 per share.
You may also be interested in...
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.